Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Enlivex Therapeutics Ltd., an Israeli company, for the month of December 2023. The filing reports on a significant clinical development milestone rather than financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical trial update.
Material Changes
On December 20, 2023, Enlivex announced the completion of enrollment for all 120 patients in its Phase II trial of Allocetra for the treatment of sepsis.
Outlook and Risks
Management commentary is limited to the announcement of the enrollment milestone. The filing does not contain specific financial guidance, risk factors, or details on contingencies beyond the referenced press release.
Investor Verification Points
- Verify the timeline for the completion of the Phase II trial and the expected date for data readout.
- Review the full text of the press release (Exhibit 99.1) for details on patient demographics and trial design.
- Check subsequent filings for updates on the trial's primary endpoints and safety data.